Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7356760 | 0.72 | DRD2 (0.56) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7363385 | 0.70 | DRD2 (0.54) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7362469 | 0.70 | SIGMAR1 (0.71) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7356651 | 0.69 | SIGMAR1 (0.69) | SIGMAR1 | |
| SCHEMBL15305255 | 0.68 | TRPA1 (0.59) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7366392 | 0.68 | DRD2 (0.55) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7358803 | 0.68 | SIGMAR1 (1.00) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7326912 | 0.68 | SIGMAR1 (0.52) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL8555351 | 0.68 | CCR3 (0.58) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10985548 | 0.67 | CYP17A1 (0.52) | DRD2HTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5296479-A | Treating physiological or drug-induced psychosis or dyskinesia | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-03-22 | — | — | US | disclosed |
| US-5266572-A | Antipsychotic 1-cycloalkylpiperidines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-30 | — | — | US | disclosed |
| US-5243048-A | Treatment of drug-induced or physiological psychosis or dyskinesia; side effect reduction | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0490962-A4 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | — | 1993-03-03 | — | — | EP | disclosed |
| EP-0490962-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| US-5109002-A | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| WO-1991003243-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |